Warner-lambert Company

Other

Pfizer Corporation

Basf Aktiengesellsschaft

Sheryl Jeanne Hays

Harry LeVine, Iii

Bradley W Caprathe

Jeffery David Scholten

John Lodge Gilmore

Juan C Jaen

Paul Galatsis

Bernd Janssen

David Juergen Wustrow

Graham Johnson

Christopher Franklin Bigge

Jay Bradford Fell

Lain-Yen Hu

Joseph Scott Warmus

Daniel Fred Ortwine

Charles J Stankovic

Corinne E Augelli-Szafran

Robert V Talanian

Mark Stephen Plummer

Hamish John Allen

Kenneth Dale Brady

Nigel P Walker

Huangshu Lei

Kimberly Suzanne Para

William Glen Harter

Aurash B Shahripour

Michael Connolly

Perry M Novak

Beth Lunney

Jeffrey David Scholten

James Knobelsdorf

Jan Ruth Penvose-Yi

The novel arylsulfonamide ether compounds, pharmaceutical compositions and uses thereof as inhibitors of interleukin-1&#x3b2; converting enzyme and other cysteine proteases in the ICE family are described. In one embodiment, the compound is described by the generalized structure:and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis, using a compound of the invention or a pharmaceutical composition thereof, are described.

Arylsulfonamide ethers, and methods of use thereof

The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases

Amyloid aggregation in animals is inhibited by administering a naphthylazo compound of the formula ##STR1## wherein R.sup.1 and R.sup.2 are hydrogen, alkyl, substituted alkyl, or complete a heterocyclic ring, R.sup.3 is hydrogen or alkyl, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are substituent groups. The compounds are especially useful in preventing and treating Alzheimer's disease.

Naphthylazo inhibition of amyloidosis

Method of imaging amyloid deposits

Inhibition of amyloidosis by 9-acridinones

The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.

Hydroxamate inhibitors of interleukin-1.beta. converting enzyme

This invention concerns certain 2-substituted-3,1-benzoxazin-4-ones and benzthiazinones as complement Clr protease inhibitors and antiinflammatory agents, pharmaceutical compositions containing them, methods of using them, and processes for their preparation.

2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as

Substituted phenoxyhydroxy amines and derivatives thereof are described as well as methods for the preparation and pharmaceutical compositions of same, which are central nervous system agents useful in the treatment of neurological disorders including traumatic brain surgery, stroke, migraine, acute and chronic pain, epilepsy, Parkinson's disease, Alzheimer's disease, amyotropic lateral sclerosis, multiple sclerosis, psychosis, and depression.

Substituted phenoxyhydroxypropyl amines as central nervous system agents

A novel series of polycyclic amines, derivatives, methods of making the compounds, novel intermediates, compositions containing them, and methods for using them in the treatment and prevention of cerebrovascular disorders are disclosed.

Polycyclic amines useful as cerebrovascular agents

Growing community of inventors

Ann Arbor, MI, United States of America

Sheryl Jeanne Hays